Cargando…
Dupilumab Treatment Leads to Rapid and Consistent Improvement of Atopic Dermatitis in All Anatomical Regions in Patients Aged 6 Months to 5 Years
INTRODUCTION: Atopic dermatitis (AD) is heterogeneous in distribution pattern and clinical features. This analysis assessed the effect of dupilumab on the extent and severity of AD across various signs (erythema, edema/papulation, excoriation, lichenification) in different anatomical regions (head a...
Autores principales: | Siegfried, Elaine C., Simpson, Eric L., Cork, Michael J., Arkwright, Peter D., Wine Lee, Lara, Chen, Zhen, Prescilla, Randy, Bansal, Ashish, Levit, Noah A., Rodríguez Marco, Ainara |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10442292/ https://www.ncbi.nlm.nih.gov/pubmed/37480432 http://dx.doi.org/10.1007/s13555-023-00960-w |
Ejemplares similares
-
Laboratory Safety from a Randomized 16-Week Phase III Study of Dupilumab in Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis
por: Paller, Amy S., et al.
Publicado: (2022) -
Dupilumab Safety and Efficacy in a Phase III Open-Label Extension Trial in Children 6–11 Years of Age with Severe Atopic Dermatitis
por: Cork, Michael J., et al.
Publicado: (2023) -
Dupilumab Demonstrates Rapid and Consistent Improvement in Extent and Signs of Atopic Dermatitis Across All Anatomical Regions in Pediatric Patients 6 Years of Age and Older
por: Simpson, Eric L., et al.
Publicado: (2021) -
Laboratory Safety of Dupilumab in Patients Aged 6–11 Years with Severe Atopic Dermatitis: Results from a Phase III Clinical Trial
por: Paller, Amy S., et al.
Publicado: (2021) -
The Posology of Dupilumab in Pediatric Patients With Atopic Dermatitis
por: Kamal, Mohamed A., et al.
Publicado: (2021)